India’s largest diagnostics service provider, Dr Lal PathLabs (DLPL), on Friday reported an 81.4 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the March quarter of financial year 2024-25 (Q4FY25) at Rs 156 crore, up from Rs 86 crore reported for the same period last year.
The company’s revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24.
On a sequential basis, the company exhibited a flat 59 per cent rise in net profit, while revenue remained flat, from Rs 98 crore and Rs 597 crore reported in Q3FY25, respectively.
The company’s earnings before interest, tax, depreciation, and amortisation (Ebitda) rose by 16.9 per cent Y-o-Y to Rs 169 crore, with the Ebitda margin coming in at 28.1 per cent in the March quarter compared to 26.5 per cent in the same period last year.
The company attributed the strong performance to increased testing volumes and its expanding footprint, particularly in Tier-III and Tier-IV towns.
